Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC)

被引：0
|
作者：
Chen, L.
Shiah, H. S.
Chen, C. Y.
Lin, Y. J.
Lin, P. W.
Su, W. C.
Chang, J. Y.
机构：
[1] Natl Hlth Res Inst, Tainan, Taiwan
[2] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4587
引用
收藏
页数：1
相关论文
共 50 条
  • [41] SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM)
    Ou, Sai-Hong Ignatius
    Moon, James
    Garland, Linda L.
    Mack, Philip C.
    Testa, Joseph R.
    Tsao, Anne S.
    Wozniak, Antoniette J.
    Gandara, David R.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) : 387 - 391
  • [42] The mTOR Inhibitor, RAD001, Inhibits the Growth of Cells From Patients with Myeloproliferative Neoplasms
    Vannucchi, Alessandro M.
    Bogani, Costanza
    Bartalucci, Niccolo
    Guglielmelli, Paola
    Tozzi, Lorenzo
    Antonioli, Elisabetta
    Pieri, Lisa
    Bosi, Alberto
    BLOOD, 2009, 114 (22) : 1139 - 1139
  • [43] A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with durvalumab, in patients (pts) with advanced hepatocellular carcinoma (HCC).
    Evans, T. R. Jeffry
    Basu, Bristi
    Hubner, Richard
    Ma, Yuk Ting
    Meyer, Tim
    Palmer, Daniel H.
    Pinato, David J. James
    Plummer, Elizabeth Ruth
    Ross, Paul J.
    Samson, Adel
    Sarker, Debashis
    Kendall, Timothy
    Bellamy, Christopher
    Reeves, Helen L.
    Thomson, Fiona
    Lawless, Claire A.
    Stobo, Jamie
    Sansom, Owen J.
    Mann, Derek A.
    Bird, Thomas G.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS631 - TPS631
  • [44] A phase I study of ganetespib in advanced hepatocellular carcinoma (HCC)
    Goyal, Lipika
    Wadlow, Raymond Couric
    Blaszkowsky, Lawrence Scott
    Wolpin, Brian M.
    Vasudev, Eamala
    Sheehan, Susan
    Knowles, Michelle
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [45] The mTOR inhibitor RAD001 augments radiation-induced growth inhibition in a hepatocellular carcinoma cell line by increasing autophagy
    Altmeyer, Anais
    Josset, Elodie
    Denis, Jean-Marc
    Gueulette, John
    Slabbert, Jakobus
    Mutter, Didier
    Noel, Georges
    Bischoff, Pierre
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2012, 41 (04) : 1381 - 1386
  • [46] Updated results of a phase I study of pasireotide (SOM230) in combination with everolimus (RAD001) in patients (pts) with advanced neuroendocrine tumors (NET).
    Chan, J. A.
    Ryan, D. P.
    Fuchs, C. S.
    Zhu, A. X.
    Abrams, T. A.
    Wolpin, B. M.
    Malinowski, P.
    Regan, E.
    Kulke, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] Pharmacokinetic (PK) and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma (HCC).
    Eckel, F
    von Delius, S
    Dobritz, M
    Fend, F
    Hosius, C
    Schleyer, E
    Schulte-Frohlinde, E
    Schmid, RM
    Lersch, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 341S - 341S
  • [48] IN VITRO STUDIES ON RESISTANCE MECHANISM IN PROSTATE CARCINOMA CELLS INDUCED BY THE MTOR INHIBITOR RAD001
    Tsaur, I
    Wedel, S. A.
    Makarevic, J.
    Bartsch, G.
    Haferkamp, A.
    Blaheta, R.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 294 - 294
  • [49] A phase I study with a daily regimen of the oral mTOR inhibitor RAD001 (Everolimus) plus sorafenib for patients with metastatic renal cell cancer (MRCC)
    Giessinger, S.
    Amato, R. J.
    Jac, J.
    Saxena, S.
    Willis, J. P.
    Chiang, S. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC) Preliminary Safety Analysis of a Single-ARM Phase II Study of Bevacizumab and Rad001
    Treiber, Gerhard
    GASTROENTEROLOGY, 2010, 138 (05) : S811 - S811
12345